The Application of Dendritic Cells Vaccines in Tumor Therapy and Their Combination with Biomimetic Nanoparticles

Vaccines, Journal Year: 2025, Volume and Issue: 13(4), P. 337 - 337

Published: March 21, 2025

Dendritic cells (DCs) act as a bridge between innate and adaptive immunity by presenting antigens to effector immune have shown broad application potential in tumor immunotherapy. However, the clinical translation of DC vaccines encounters significant challenges, such immunosuppressive microenvironment (TME) sub-optimal function vaccine efficacy vivo. In this review, our investigation has uncovered latest developments their cancer immunotherapy, with special emphasis on integration nanotechnology. Several types nanomaterials, including protein cage nanoparticles (NPs), biomimetic NPs, targeted multifunctional been developed enhance antigen presentation ability DCs stimulatory effects T cells. addition, we also summarized synergistic anti-cancer checkpoint inhibitors, chemotherapy, radiotherapy. recent advances nanotechnology made it possible develop novel biomarkers that can capacity stimulate These not only improve accuracy precision design but provide new insights into understanding mechanisms DC-mediated response. Despite challenges pertaining technical complexities individual adaptation production vaccines, personalized immunotherapy based is expected become an important part treatment rapid biotechnology immunology. This review provides perspectives solutions for optimal therapy.

Language: Английский

---

UiO-based platforms in biomedicine: Advanced nanovehicles for effective treatment

Materials Today Chemistry, Journal Year: 2025, Volume and Issue: 45, P. 102645 - 102645

Published: March 22, 2025

Language: Английский

---

Stable liposomal cerasome for ultrasound/H2O2-activated CO release to augment tumor chemotherapy and immunotherapy

Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: unknown, P. 161398 - 161398

Published: March 1, 2025

Language: Английский

---

A Glutathione‐Responsive System with Prodrug and Sensitization Strategies for Targeted Therapy of Glioma

Small, Journal Year: 2025, Volume and Issue: unknown

Published: March 22, 2025

Abstract Glioblastoma represents a highly aggressive form of malignant tumor within the central nervous system. Although chemotherapy remains primary therapeutic strategy, its efficacy is often limited. To overcome limitations associated with chemotherapeutic agents, such as high toxicity and non‐specific adverse effects, novel nanoparticle system comprising cRGD‐modified glutathione (GSH)‐responsive polymers, PEG‐ss‐Dox apatinib (AP) (PDOX‐AP/cRGD‐NPs) developed. PDOX‐AP/cRGD‐NPs show effective penetration blood‐brain barrier (BBB), facilitate targeted delivery to brain tumors, exhibit controlled drug release. more effect in reducing viability GL‐261, U87‐MG, LN‐229 cells, inhibiting clonogenicity, suppressing anti‐apoptotic protein expression than PDOX/cRGD‐NPs or AP/cRGD‐NPs. Additionally, substantially increase uptake, BBB penetration, apoptosis rates, proportion cells G2 phase. In vivo experiments further reveal that cRGD‐directed nanoparticles superior accumulation glioma regions compared their non‐cRGD‐modified counterparts. interim, demonstrate significant both ectopic orthotopic growth GL‐261 gliomas, well thereby markedly extending median survival duration. This study introduces promising co‐delivery for combination chemotherapy.

Language: Английский

---

PD-L1 targeted antibody-polymer-Epirubicin conjugate prolongs survival in a preclinical murine model of advanced ovarian cancer

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: unknown, P. 113682 - 113682

Published: April 1, 2025

Following successful design of polymer enhanced rituximab-epirubicin (EPI) conjugates targeted to non-Hodgkin lymphoma (Zhang et al. 2017), we developed U6244-051 that consists anti-PD-L1 antibody (αPD-L1) and semitelechelic N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-epirubicin (ST-P-EPI); the latter is attached αPD-L1 via Cu-free azide/alkyne cycloaddition. This new polymer-enhanced antibody-drug conjugate (pADC) not only exhibits a high drug-to-antibody ratio (DAR ~ 30-40) but also integrates immune checkpoint blockade with long-lasting immunogenic anticancer chemotherapy, providing an innovative chemo-immuno combination modality. The biological properties were evaluated using ID8-Luc murine ovarian cancer cells in vitro vivo. In vitro, treatment induced immunomodulatory changes, including upregulation calreticulin, PD-L1, MHC I, suggesting tumor cell visibility system. vivo efficacy was assessed syngeneic model (C57BL/6 J mice inoculated 5 × 106 cells/mouse). resulted 100 % survival at day 100, despite initiation advanced disease stage. Treatment modulated microenvironment by reducing immunosuppressive populations (TAMs MDSCs) enhancing T recruitment activation. A decrease PD-L1 expression increased I correlated immune-mediated clearance. Additionally, reduced Treg levels CD8+ activation contributed more effective antitumor response. Repeated dosing amplified effects, leading durable immunity. These results highlight as next-generation pADC translational potential, offering on-target, off-tumor toxicity.

Language: Английский

---

Blood–Brain Barrier-Permeable, Reactive Oxygen Species-Producing, and Mitochondria-Targeting Nanosystem Amplifies Glioblastoma Therapy

ACS Applied Materials & Interfaces, Journal Year: 2025, Volume and Issue: unknown

Published: April 27, 2025

Gemcitabine (GTB), a clinically approved nucleoside analogue for cancer treatment, faces therapeutic limitations due to rapid enzymatic deactivation by cytidine deaminase (CDA) in tumor microenvironments. Over 90% of systemically administered GTB undergoes catalytic conversion inactive 2'-deoxy-2',2'-difluorouracil metabolites through CDA-mediated deamination. To address this pharmacological challenge, we developed multifunctional codelivery nanosystem strategic engineering reactive oxygen species (ROS)-generating, mitochondria-targeting CPUL1-TPP (CT) nanoaggregates. These self-assembling CT/GTB complexes were further optimized with DSPE-MPEG2k (DP) and Angiopep-2-conjugated (Ang-DP) create blood-brain barrier (BBB)-penetrating Ang-DP@CT/GTB nanoparticles, enhancing both physiological stability low-density lipoprotein receptor-related protein 1 (LRP1)-mediated glioma targeting. Comparative analyses revealed that nanoparticles significantly enhanced GTB's antiglioblastoma efficacy compared free drug administration vitro vivo models. Mechanistic investigations demonstrated the upregulates heme oxygenase-1 (HO-1), subsequently downregulating CDA expression mitigate metabolism. This coordinated molecular modulation prolongs activity while leveraging ROS-generating capacity CT components synergistic suppression. The BBB-permeable platform exemplifies rational design paradigm carrier-free pure nanodrugs (PNDs), demonstrating how clinical reformulation can overcome inherent pharmacokinetic limitations. nanotechnology-driven approach provides critical insights optimizing chemotherapeutic performance metabolic pathway regulation targeted delivery engineering.

Language: Английский

---

Ni–Cu Bimetallic Nanozyme and Minoxidil Co-Loaded Dissolving Microneedles Reshape Hair Follicle Microenvironment for Androgenic Alopecia Treatment

ACS Applied Nano Materials, Journal Year: 2025, Volume and Issue: unknown

Published: April 28, 2025

Language: Английский

---

Engineering a Tumor‐Acidity‐Responsive PEG‐Sheddable Nanoassembly for Combating Drug Resistance

Macromolecular Chemistry and Physics, Journal Year: 2025, Volume and Issue: unknown

Published: May 2, 2025

Abstract This study presents a simple strategy to develop tumor‐acidity responsive core‐crosslinked micellar nanoassembly capable of delivering multiple drugs combat drug resistance. Paclitaxel (PTX) nanocrystals are prepared using D‐α‐tocopherol polyethylene glycol 1000 succinate (TPGS) as an emulsifier and cross‐linked with poly(β‐cyclodextrin) (PCD) form the core. An acid‐labile prodrug, poly(ethylene glycol)‐doxorubicin (mPEG‐DOX), is utilized shell, forming core‐shell (CSNA) via supramolecular interactions. The CSNA demonstrated high stability in aqueous serum environments, triggered shell‐detachment response tumor acidity. nanomedicine exhibited superior inhibition drug‐resistant cancer cell line MCF‐7/ADR compared DOX or PTX alone, offering potential overcome resistance chemotherapy.

Language: Английский

---

Orchestrated Molecularly Imprinted Nanoparticles for Tumor-Targeted and Chemo-Photothermal Therapy

ACS Applied Materials & Interfaces, Journal Year: 2025, Volume and Issue: unknown

Published: May 6, 2025

Effective eradication of cancer cells while minimizing damage to normal tissues remains a significant challenge in clinical oncology. Herein, multifunctional nanoplatform (DFD-MIP) was developed through sequential fabrication doxorubicin (DOX)-loaded inner layer and P32 epitope-imprinted outer on Fe3O4 nanoparticles (NPs), using dopamine as both functional monomer cross-linker. To assess therapeutic superiority DFD-MIP, comprehensive vitro vivo studies were conducted. Results demonstrated that the served an artificial antibody for overexpressed tumor cell recognition "gatekeeper" prevent drug leakage during circulation, thereby reducing systemic toxicity. Upon cellular internalization, acidic microenvironment triggered degradation polydopamine (PDA)-based layers, enabling pH-responsive DOX release directly within cells. Synergistically, under 808 nm near-infrared irradiation, combined photothermal conversion capabilities NPs PDA residues generated enhanced hyperthermia. This chemo-photothermal combination therapy achieved superior suppression localized activation thermal ablation residual DFD-MIP integrated multiple desirable features including simplified composition, active targeting capability, excellent biocompatibility, prolonged retention, release. platform significantly improves chemotherapeutic bioavailability off-target effects, providing prototype development targeted delivery systems.

Language: Английский

---

Advanced Precision Dual Photothermal and Photodynamic Therapy for Prostate Cancer Using PSMA-ICG-Conjugated Gold Nanorods

ACS Biomaterials Science & Engineering, Journal Year: 2025, Volume and Issue: unknown

Published: May 8, 2025

Prostate cancer is the second most common among men globally. In this study, we developed a prostate-cancer-targeted gold nanoparticle-based photothermal and photodynamic complex (GNR-ICG-FA@PSMA) to enhance targeting efficiency of prostate cells simultaneously deliver therapy (PTT) (PDT). For in vitro tests, ROS assays, annexin V/PI staining, MTT assays were conducted. vivo fluorescence photoacoustic imaging systems used track distribution nanoparticles animal models. Tumor tissues analyzed post-treatment using Triphenyl tetrazolium chloride (TTC) Hematoxylin Eosin (HE) Immunohistochemistry (IHC) staining. The results showed that GNR-ICG with laser irradiation produced high levels ROS, highest rate apoptosis, lowest cell viability. tail-injected GNR-ICG-FA@PSMA reached tumor within 9 h. During irradiation, GNRs increased temperature (<50 °C), inducing necrosis, while ICGs generated leading apoptosis. demonstrated folic acid (FA) PSMA antibodies improved cancer-specific targeting. contributed effects, respectively. This study confirms potential for targeted cancer.

Language: Английский

---